Business

The Food and Drug Administration recently authorized Novavax’s protein-based Covid-19 vaccine for emergency use in individuals aged 12 and above. This approval comes as a significant development in the fight against the pandemic, as it provides another option for vaccination alongside the Pfizer and Moderna vaccines. Novavax’s vaccine is specifically designed to target the omicron
0 Comments